Biopharmaceuticals and Protein Analysis

Latest News


meeting.jpg

The Column

Mass spectrometry (MS) is emerging as a critical tool in biopharmaceutical late stage development, manufacturing, and quality control (QC) environments. The rapid growth of biologics in development, the increasing demand for more robust analytical technologies to directly monitor the critical quality attributes (CQAs) of these new drugs, and longer term industry initiatives aimed at improving quality and productivity, such as quality by design (QbD) regulatory submissions and continuous manufacturing, are all fueling a greater need for mass monitoring with MS.

Francois-figure-01_web-1-New-14452693443131445285426135.jpg

Special Issues

An analytical methodology for the characterization of the primary structure of biotherapeutic proteins using sheathless CE–ESI-MS-MS instrumentation is presented. For the first time, complete sequence coverage can be achieved using a bottom-up proteomic approach from a single analysis of a tryptic digest. In a biosimilarity assessment, a single amino acid substitution was detected.

JPMota.jpg

The biopharmaceutical industry continues to expand in response to a demand for novel biopharmaceuticals. LCGC spoke to José Paulo Mota from the Faculty of Science and Engineering (FCT-UNL) of Universidade Nova de Lisboa, Portugal, and Institute of Experimental and Technological Biology (IBET), Portugal, about the development of novel downstream purification strategies.

MassSpec3_i9_t-856308-1417773405174.gif

Special Issues

This article describes the development of a new data-independent acquisition (DIA) workflow for protein quantification that uses a mass spectrometer that combines three types of mass analyzers to achieve lower limits of detection (LOD), higher sensitivity, more accurate quantitative results, wider dynamic range, and better reproducibility than existing high-resolution accurate-mass (HRAM) tandem mass spectrometry (MS-MS) DIA workflows.